This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer: This Froth Has to Be Reined In

NEW YORK ( Real Money) -- You can't stop the froth, even in the midst of a new Cold War between Russia and the West. You can't stop it even as major stocks seem to be rolling over left and right. You can't stop it even when the established stocks in a group are getting crushed but initial public offerings in the same sector come along and roar.

Take last Friday. Castlight Health (CSLT) came public to tremendous fanfare, soaring 140% the first day. Why? Because this is a company that offers a software-as-a-service cloud-based solution for health care benefits. Whoop-de-do. Have you seen how badly (CRM), Workday (WDAY), Veeva (VEEV) and Concur Technologies (CNQR) shares have been trading after excellent quarters? These companies are the cream of the crop, and they have been fabulous shorts for two weeks now -- and we like Castlight?

I suspect this week will be more of the same when several other names come public: Paylocity, a cloud-based payroll-and-human-capital company; Q2 Holdings, a cloud-based community­-banking play; Amber Road, a global trade cloud-based company; and Globoforce, a cloud-based social-recognition software business. (Ticker symbols will be "PTCY," "QTWO," "AMBR" and "THNX," respectively).

These are all versions of what could easily be described as existing companies. In fact, Paylocity sounds like Workday-meets-Cornerstone OnDemand (CSOD). As for Q2 Holdings, has a community-banking initiative -- check its site. Cloud-based social recognition and global trade businesses? I am sure Globoforce and Amber Road have something proprietary, but I have to ask: "Do you really need to come public now?" What's the darned hurry? The answer, of course, is that the public market is divorced right now from the soon-to-be public IPOs, and that is always a bad sign.

Must Read: Ukraine Situation; Bonds; Market Weakness: Best of Kass

It's the same thing with biotech. Upcoming IPOs for Akebia Therapeutics, an antianemia therapy company and for Versartis, a growth-hormone play, presumably will dazzle (under respective tickers "AKBA" and "VSAR") -- even as Celgene (CELG), Gilead (GILD), Isis (ISIS), Jazz (JAZZ) and Seattle Genetics (SGEN) are becoming unglued.

Now, I happen to like the incumbents. I am not making a judgment about those. I think the incumbents that I have mentioned here in the cloud and biotech spaces will come back. Many are fine companies.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs